KATHRYN BURNS: Open Payments
NPI 1679818041 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,048 in 25 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,048
Food & beverage: $1,048
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $354 |
| Amgen Inc. | 2 | $169 |
| Ardelyx, Inc. | 3 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $88 |
| Novo Nordisk Inc | 2 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $40 |
| GENZYME CORPORATION | 1 | $33 |
| ABIOMED | 1 | $29 |
| Janssen Biotech, Inc. | 1 | $29 |
Products named: REZDIFFRA, UPLIZNA, IBSRELA, XIFAXAN, DUPIXENT, Wegovy, REBYOTA, TREMFYA.
Industry payments across FL — which companies pay providers there.
